Appendix I: References for included and cited studies


Ahmadieh H, Taei R, Riazi-Esfahani M et al. (2011) Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial Retina 31 1819-1826


Amoaku WM, Chakravarthy U, Gale R et al. (2015) Defining response to anti-VEGF therapies in neovascular AMD Eye 29 (6) 721-731

Arias L, Armada F, Donate J et al. (2009) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss Eye 23 (2) 326-333


Bartlett HE, Eperjesi F (2007) Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial European journal of clinical nutrition 61 (9) 1121-1127

Bashshur ZF, Schakal AR, El-Mollayess GM et al. (2011) Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration Retina (Philadelphia, Pa.) 31 636-644

Batioglu F, Demirel S, Ozmert E et al. (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD BMC ophthalmol 15 40-
Beatty S, Chakravarthy U, Nolan JM et al. (2013) Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration Ophthalmology 120 (3) 600-606

Berg K, Pedersen TR, Sandvik L et al. (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 (1) 146-152


Biswas P, Sengupta S, Choudhary R et al. (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian journal of ophthalmology 59 (3) 191-

Bittner AK, Torr-Brown S, Arnold E et al. (2014) Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial Journal of clinical & experimental ophthalmology 5 (1) 320-


Boulanger-Scemama E, Querques G, About F et al. (2015) Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting Journal Francais d Opthalmologie 38 620-627

Brader HS, Ying GS, Martin ER et al. (2011) New grading criteria allow for earlier detection of geographic atrophy in clinical trials Investigative ophthalmology & visual science 52 (12) 9218-9225

Bressler SB, Maguire MG, Bressler NM et al. (1990) Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group Archives of ophthalmology (Chicago, Ill.: 1960) 1442-1447


Brody BL, Roch-Levecq AC, Thomas RG et al. (2005) Self-management of age-related macular degeneration at the 6-month follow-up: a randomized controlled trial Archives of Ophthalmology 123 (1) 46-53


Buckle M, Donachie PH, Johnston RL (2016) Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK British Journal of Ophthalmology 100 (2) 240-245


Burton AE, Shaw RL, Gibson JM (2013) "I'd like to know what causes it, you know, anything I've done?" Are we meeting the information and support needs of patients with macular degeneration? A qualitative study BMJ Open 3 (11) e003306


Busbee BG, Ho AC, Brown DM et al. (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 (5) 1046-1056

Busija L, Pausenberger E, Haines TP et al. (2011) Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36 Item (SF 36) and Short Form 12 Item (SF12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF 6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-being Scale (QWB), and Assessment of Quality of Life (AQOL) Arthritis care & research 63 (S11) S383-S412


Cachulo L, Silva R, Fonseca P et al. (2010) Early markers of choroidal neovascularization in the fellow eye of patients with unilateral exudative age-related macular degeneration Ophthalmologica 225 (3) 144-149

Macular Degeneration
Appendix I: References for included and cited studies

Chakravarthy U, Wong TY, Fletcher A et al. (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis BMC ophthalmology 10 (1) 31-

Chakravarthy U, Harding SP, Rogers CA et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 (7) 1399-1411

Chakravarthy U, Harding SP, Rogers CA et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial The Lancet 382 (9900) 1258-1267

Chakravarthy U, Harding SP, Rogers CA et al. (2015) A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)


Chang AA, Li H, Broadhead GK et al. (2013) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration 41 52-

Chang AA, Li H, Broadhead GK et al. (2014) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Ophthalmology 121 188-192

Chasan JE, Delaune B, Maa AY et al. (2014) Effect of a teleretinal screening program on eye care use and resources JAMA Ophthalmology 132 (9) 1045-1051

Cheong AM, Lovie-Kitchin JE, Bowers AR et al. (2005) Short-term in-office practice improves reading performance with stand magnifiers for people with AMD Optometry and vision science 82 (2) 114-127

Cheung CMG, Yanagi Y, Mohla A et al. (2016) Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography Retina no-


Chew EY, Clemons TE, Bressler SB et al. (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study Ophthalmology 121 535-544


Christen WG, Glynn RJ, Chew EY et al. (2009) Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women Ophthalmology 2386-2392


Cohen SY, Creuzot-Garcher C, Darmon J et al. (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration The British journal of ophthalmology 91 (9) 1173-1176


Curtis, L. and Burns, A. (2016) Unit costs of health and social care 2016. Personal Social Services Research Unit, University of Kent.


Dahlin I, S, Sjostrand J et al. (1996) Planning a health education programme for the elderly visually impaired person - A focus group study Disability and Rehabilitation 18 (10) 515-522

Dakin HA, Wordsworth S, Rogers CA et al. (2014) Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial BMJ Open 4 (7) e005094-

Danis RP, Domalpally A, Chew EY et al. (2013) Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2) Investigative ophthalmology & visual science 54 (7) 4548-4554


Davis S, Stevenson M, Tappenden P et al. (2014) NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation School of Health and Related Research, University of Sheffield

de Carlo T, Bonini Filho MA, Chin AT et al. (2015) Spectral Domain Optical Coherence Tomography Angiography (OCTA) of Choroidal Neovascularization Investigative ophthalmology & visual science 56 (7) 3962-3962


Department of Health (2016) Drugs and pharmaceutical electronic market information (eMit)


Dobbelsteyn D, McKee K, Bearnes RD et al. (2015) What percentage of patients presenting for routine eye examinations require referral for secondary care? A study of referrals from optometrists to ophthalmologists Clinical & Experimental Optometry 98 (3) 214-217

Droege KM, Muether PS, Hermann MM et al. (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life Graefes Archive for Clinical & Experimental Ophthalmology 251 1281-1284

Eadie JA, Gottlieb JL, Ip MS et al. (2014) Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration Ophthalmic Surg Lasers Imaging Retina 45 394-397
Ehiksen C, Jungmann S, Bohringer D et al. (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD Eye 28 538-545


El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2013) Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity Retina 33 (9) 1828-1835


Eldem BM, Muftuoglu G, Topbas S et al. (2015) A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD Acta Ophthalmologica 93 (6) e458-e464


Elshout M, van der Reis MI, Webers CA et al. (2012) A new epidemiological aid in deciding whether to continue or stop a treatment Invest Ophthalmol Vis Sci 53 4331-4336

Elshout M, van der Reis MI, Webers CA et al. (2014) The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters Graefe's archive for clinical and experimental ophthalmology 252 (12) 1911-1920


Eter N, Spaide RF (2005) Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy Retina 25 (6) 691-696

Evans JR, Lawrenson JG (2012) Antioxidant vitamin and mineral supplements for slowing the progression of age related macular degeneration The Cochrane Library

Fang K, Tian J, Qing X et al. (2013) Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration Journal of ophthalmology 2013 676049-


Figueroa MS, Regueras A, Bertrand J (1994) Laser photocoagulation to treat macular soft drusen in age-related macular degeneration Retina 14 (5) 391-396

Macular Degeneration
Appendix I: References for included and cited studies

Fleiss JL (1971) Measuring nominal scale agreement among many raters Psychological bulletin 76 (5) 378-


Friberg TR, Brennen PM, Freeman WR (2009) Prophylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients Ophthalmic Surgery, Lasers & Imaging Retina 40 (6) 530-


Gehlbach P, Li T, Hatef E (2015) S Cochrane Library

Gerding H (2015) Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment Klinische Monatsblatter fur Augenheilkunde 232 (4) 560-563


Ghosh W, Wickstead R, Claxton L et al. (2016) The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK Advances in therapy 33 (9) 1660-1676

Giani A, Luiselli C, Esmaili DD et al. (2011) Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization Investigative ophthalmology & visual science 52 (8) 5579-5586

Gillespie BW, Musch DC, Niziol LM et al. (2014) Estimating Minimally Important Differences for Two Vision-Specific Quality of Life MeasuresMinimally Important Difference for NEI-VFQ and VAQ Investigative ophthalmology & visual science 55 (7) 4206-4212

Gillies MC, Campain A, Barthelmes D et al. (2015) Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Ophthalmology 122 (9) 1837-1845


Goudie C, Lunt D, Reid S et al. (2014) Ophthalmic digital image transfer: benefits to triage, patient care and resource Ophthalmic & Physiological Optics 34 (6) 628-635


Griffin DR, Richmond PP, Olson JC (2014) Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration J Ophthalmol 2014 497178-

Grunwald JE, Daniel E, Huang J et al. (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 150-161

Guymer RH, Baird PN, Varsamidis M et al. (2013) Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration PLoS One 8 (12) e83759-

Hageman GS, Gehrs K, Johnson LV et al. (2008) Age-related macular degeneration (AMD)

Hahn P, Acquah K, Cousins SW et al. (2013) Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries Retina (Philadelphia, Pa.)Retina 911-919


Hariri A, Diniz B, Fou LV, Lam LA, Nittala MG, Sadda SR. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina 2015; 46(2):195-200

Hatz K, Schneider U, Henrich PB et al. (2015) Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study Ophthalmologica 233 66-73


Heier JS, Boyer D, Nguyen QD et al. (2011) The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing Ophthalmology 118 (6) 1098-1106


Hirneiss C (2014) The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life Clinical ophthalmology (Auckland, NZ) 8 1703-


Homer N, Grewal DS, Mirza RG et al. (2015) Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results Eye 29 1152-1155


Howard KP, Klein Barbara EK, Lee KE et al. (2014) Measures of body shape and adiposity as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye Study Investigative ophthalmology & visual scienceInvest Ophthalmol Vis Sci  2592-2598


Jaeschke R, Guyatt GH, Sackett DL et al. (1994) Users’ Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test B. What Are the Results and Will They Help Me in Caring for My Patients? JAMA 271 (9) 703-707

Jorstad OK, Faber RT, Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol 2017


Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension Graefes archive for clinical and experimental ophthalmology 244 (9) 1132-1142


Kaltenthaler E, Tappenden P, Paisley S et al. (2011) NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models Sheffield: Decision Support Unit, ScHARR, University of Sheffield


Khurana RN, Dupas B, Bressler NM (2010) Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization Ophthalmology 117 (7) 1376-1380


Klein Barbara EK, Howard KP, Gangnon RE et al. (2012) Long-term use of aspirin and age-related macular degeneration JAMA 2469-2478


Klein R, Klein BE, Knudtson MD et al. (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study Ophthalmology 253-262

Macular Degeneration
Appendix I: References for included and cited studies

Klein R, Meuer SM, Myers CE et al. (2014) Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium Ophthalmic epidemiology 21 (1) 14-23

Klein R, Knudtson MD, Cruickshanks KJ et al. (2008) Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study Archives of ophthalmology (Chicago, Ill.: 1960) 115-121


Kodjikian L, Souied EH, Mimoun G et al. (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial Ophthalmology 120 (11) 2300-2309

Koh A, Lee WK, Chen LJ et al. (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 1453-1464

Krebs I, Vecsei M, V et al. (2013) Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration Acta Ophthalmologica 91 e178-e183

Krebs I, Schmetterer L, Boltz A et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration British Journal of Ophthalmology 97 (3) 266-271


Kumar N, Marsiglia M, Mrejen S et al. (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration Retina 33 1605-1612

Kuppermann BD, Goldstein M, Maturi RK et al. (2015) Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial Ophthalmologica 234 40-54


Lawrenson JG, Evans JR (2015) Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration The Cochrane Library


Lechanteur Yara TE, van d, V, Johannes PH et al. (2012) Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration
Macular Degeneration
Appendix I: References for included and cited studies

degeneration Investigative ophthalmology & visual science 5846-5852

Li B, Powell AM, Hooper PL et al. (2015) Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial JAMA Ophthalmology 133 (3) 276-282


Lim JI, Labree L, Nichols T et al. (2002) Comparison of nonmydriatic digitized video fundus images with standard 35-mm slides to screen for and identify specific lesions of age-related macular degeneration Retina 22 (1) 59-64


Lushchyk T, Amarakoon S, Martinez-Ciriano J et al. (2013) Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks Acta ophthalmologica 91 (6) e456-e461


Maguire MG, Bressler SB, Bressler NM et al. (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Archives of Ophthalmology 115 (6) 741-747

Maguire MG, Ying GS, McCannel CA et al. (2009) Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial Ophthalmology 116 (12) 2381-2385


Mantel I, Gianniou C, Dirani A (2016) Conversion to Aflibercept Therapy Versus Continuing with Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration Dependent on Monthly Ranibizumab Treatment Retina 36 53-58


McCloud C, Khadka J, Gilhotra JS et al. (2014) Divergence in the lived experience of people with macular degeneration Optometry & Vision Science 91 966-974


Menon G, Chandran M, Sivaprasad S et al. (2013) Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab&quest;(BeMOc Trial) Eye 27 (8) 959-963


Mokwa NF, Ristau T, Keane PA et al. (2013) Grading of age-related macular degeneration: comparison between color fundus photography, fluorescein angiography, and spectral domain optical coherence tomography Journal of ophthalmology 2013

Mowatt G, Hernández R, Castillo M et al. (2014) Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation Health Technology Assessment

Muen WJ, Hewick SA (2011) Quality of optometry referrals to neovascular age-related macular degeneration clinic: a prospective study JRSM Short Reports 2 (8) 64-

Muether PS, Hermann MM, Koch K et al. (2011) Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity Graefes Archive for Clinical & Experimental Ophthalmology 249 (5) 633-637


Murray IJ, Makridaki M, van der Veen RL et al. (2013) Lutein Supplementation over a One-Year Period in Early AMD Might Have a Mild Beneficial Effect on Visual Acuity: The CLEAR Study Effect of Lutein Supplementation on Visual Acuity Investigative ophthalmology & visual science 54 (3) 1781-1788

Narayan DS, Muecke J (2015) Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab Indian J Ophthalmol 63 832-836


National Institute for Health and Care Excellence (2013) Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance (TA294)


National Institute for Health and Care Excellence (2016) Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline (CG181)


Appendix I: References for included and cited studies


Nixon DR, Flinn NA. Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab. Clin Ophthal 2017; 11:715-721


Oliver-Fernandez A, Bakal J, Segal S et al. (2005) Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration Canadian Journal of Ophthalmology 40 (3) 313-319


Olsen TW, Feng X, Kasper TJ et al. (2004) Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration Ophthalmology 111 (2) 250-255


Padnick-Silver L, Weinberg AB, Lafranco FP et al. (2012) Pilot study for the detection of early exudative age-related macular degeneration with optical coherence tomography Retina 32 (6) 1045-1056


Patel KH, Chow CC, Rathod R et al. (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab Eye 27 663-667
Perlee LT, Bansal AT, Gehrs K et al. (2013) Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy Ophthalmology 120 (9) 1880-1892

Piermarocchi S, Saviano S, Parisi V et al. (2012) Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study European Journal of Ophthalmology 22 (2) 216-

Pinheiro-Costa J, Costa JM, Beato JN et al. (2015) Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice Ophthalmologica 233 155-161


Piri N, Ahmadieh H, Taei R et al. (2014) Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial Journal of Ophthalmic & Vision Research 9 469-477


Ranchod TM, Ray SK, Daniels SA et al. (2013) LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration Retina 33 1600-1604


Rasul A, Subhi Y, Sorensen TL et al. (2016) Non-Physician delivered intravitreal injection service is feasible and safe - A systematic review Danish Medical Journal 63 (5) no-


Real JP, Luna JD, Urrets-Zavalia JA et al. (2013) Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration European Journal of Ophthalmology 23 (6) 857-864


Reeves BC, Scott LJ, Taylor J et al. (2016) Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial BMJ Open 6 (7) e010685-


Reynolds R, Rosner B, Seddon JM (2013) Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 1020-1028


Rofagha S, Bhisitkul RB, Boyer DS et al. (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 (11) 2292-2299


Rovner BW, Casten RJ, Hegel MT et al. (2007) Preventing depression in age-related macular degeneration Archives of General Psychiatry 64 (8) 886-892

Rovner BW, Casten RJ, Hegel MT et al. (2013) Improving function in age-related macular degeneration: a randomized clinical trial Ophthalmology 120 (8) 1649-1655

Rovner BW, Casten RJ, Hegel MT et al. (2014) Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial Ophthalmology 121 (11) 2204-2211


Saito M, Kano M, Itagaki K et al. (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab Retina 34 2192-2201

Saito M, Kano M, Itagaki K et al. (2016) Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection Jpn J Ophthalmol 60 35-41


Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes British Journal of Ophthalmology 89 (8) 967-970
Sarao V, Parravano M, Veritti D et al. (2016) Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy Retina 36 (4) 770-777


Schauwvlieghe AME, Dijkman G, Hooymans JM et al. (2016) Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study PLoS One 11 (5) no-


Schmier JK, Halpern MT, Covert D et al. (2006) Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration Retina 26 (9) 1056-1062


Seddon JM, Cote J, Davis N et al. (2003) Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio Archives of ophthalmology (Chicago, Ill.: 1960) 785-792


Seddon JM, Reynolds R, Yu Y et al. (2011) Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors Ophthalmology 2203-2211

Seddon JM, Reynolds R, Yu Y et al. (2013) Validation of a prediction algorithm for progression to advanced macular degeneration subtypes JAMA ophthalmologyJAMA Ophthalmol 448-455

Seddon JM, Silver RE, Kwong M et al. (2015) Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates Investigative ophthalmology &amp; visual scienceInvest Ophthalmol Vis Sci 2192-2202

Semeraro F, Russo A, Delcassi L et al. (2015) Treatment of Exudative Age-Related Macular Degeneration with Ranibizumab Combined with Ketorolac Eyedrops or Photodynamic Therapy Retina 35 1547-1554


Shea BJ, Grimshaw JM, Wells GA et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC medical research methodology 7 (1) 10-

Shiragami C, Ono A, Kobayashi M et al. (2014) Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration 93 no-

Simcock P, Kingett B, Mann N et al. (2014) A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners Eye (Basingstoke) 28 (10) 1161-1164


Smith HJ, Dickinson CM, Cacho I et al. (2005) A randomized controlled trial to determine the effectiveness of prism spectacles for patients with age-related macular degeneration Archives of Ophthalmology 123 (8) 1042-1050

Solomon SD, Lindsley K, Vedula SS et al. (2014) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration The Cochrane Library

Souied EH, Delcourt C+, Querques G et al. (2013) Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study Ophthalmology 120 (8) 1619-1631

Stein JD, VanderBeek BL, Taiwar N et al. (2011) Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups Investigative ophthalmology & visual science 6842-6848

Stein JD, Newman-Casey PA, Mrinalini T et al. (2014) Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration Ophthalmology 121 (4) 936-945


Stur M, Tittl M, Reitner A et al. (1996) Oral zinc and the second eye in age-related macular degeneration Investigative ophthalmology & visual science 37 (7) 1225-1235


Sunness JS, Gonzalez-Baron J, Applegate CA et al. (1999) Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 106 (9) 1768-1779


The Royal College of Ophthalmologists (2013) Age-related macular degeneration: guidelines for management. London:

Thompson AC, Thompson MO, Young DL et al. (2015) Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases. Investigative ophthalmology & visual science 56 4324-4331

Thorell MR, Nunes RP, Chen GW et al. (2014) Response to aflibercept after frequent retreatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina 45 526-533


Van dm, A, Sandhu SS et al. (2006) Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes British Journal of Ophthalmology 90 (3) 304-306


van LR, Boekhoorn S, Vingerling JR et al. (2005) Dietary intake of antioxidants and risk of age-related macular degeneration JAMA 3101-3107

van V, M E, de S et al. (2006) Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT Graefes Archive for Clinical & Experimental Ophthalmology 244 (9) 1119-1123


Varano M, Eter N, Winyard S et al. (2015) Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey Clinical Ophthalmology 9 2243-2250

Vaze A, Fraser-Bell S, Gillies M (2014) Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Retina 34 1774-1778

Verteporfin In Photodynamic Therapy Study (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizationâ€”verteporfin in photodynamic therapy report 2 American Journal of Ophthalmology 131 (5) 541-560

Virgili G, Michelessi M, Parodi MB et al. (2015) Laser treatment of drusen to prevent progression to advanced age â€”related macular degeneration The Cochrane Library

Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial Archives of Ophthalmology 123 (4) 448-

Vogel RN, Davis DB, Kimura BH et al. (2016) Neovascular age-related macular degeneration with advanced visual loss treated with anti-vascular endothelial growth factor therapy: Clinical Outcome and Prognostic Indicators Retina no-

Vottonen P, Kankaanp E (2016) Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model Acta ophthalmologica 94 (7) 652-656

Vukicevic M, Fitzmaurice K (2005) Rehabilitation strategies used to ameliorate the impact of centre field loss Visual Impairment Research 7 79-84


Vukicevic M, Heraghty J, Cummins R et al. (2016) Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration Eye 30 (3) 413-421


Williams TA, Blyth CP (2011) Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12 Eye 25 (12) 1617-1621


Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 2014; 98(7):951-955


Ying GS, Huang J, Maguire MG et al. (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 (1) 122-129


Yuzawa M, Fujita K, Wittrup-Jensen K et al. (2015) Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration Ophthalmology 122 (3) 571-578
